Perspective Therapeutics, Inc. (CATX)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$3.13+0.32%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CATX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress clinical development of VMT-α-NET, VMT01, PSV359, and PSV594 with key data readouts and Phase 3 study initiation planned in 2026.
Stated as a priority in 2 of last 2 quarters. Clinical programs including VMT-α-NET, VMT01, and PSV359 advanced with 76 NET patients treated as of 2026-Q2 and Phase 3 site activation targeted by year-end 2026. Management's trajectory is delivering with ongoing patient dosing and clinical catalysts expected in 2026.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, site activation targeted around year-end 2026.”
“Three clinical-stage oncology programs advancing with multiple clinical catalysts expected in 2026.”
Complete construction of Chicago manufacturing site in early 2027 and Los Angeles site in second half of 2027 to support clinical and commercial supply.
Stated in 2 of last 2 quarters. Management reports Chicago manufacturing site construction on track for early 2027 completion and Los Angeles site planned for second half of 2027, expanding to four regional sites by end of 2027. The trajectory is delivering consistent progress on manufacturing infrastructure.
“Chicago metro site to complete construction in early 2027; Los Angeles site in 2H 2027.”
“Regional manufacturing network designed to support reliable supply; Chicago site expected to complete construction in 2026.”
Maintain sufficient cash, cash equivalents, and short-term investments to support clinical and operational activities through late 2027.
Stated in 3 of last 3 quarters. Cash, cash equivalents, and short-term investments increased from approximately $145 million at 2025-Q4 to $237 million at 2026-Q2, supporting funding of clinical milestones and operations into late 2027. Management is delivering on maintaining sufficient liquidity.
“Cash, cash equivalents, and short-term investments approximately $237 million as of June 30, 2026; sufficient to fund clinical milestones into late 2027.”
“Cash, cash equivalents, and short-term investments approximately $271 million as of March 31, 2026; sufficient to fund clinical milestones into late 2027.”
“Cash and equivalents approximately $145 million as of December 31, 2025.”
Control operating losses with increased investment in research and development to advance clinical programs.
Stated in 2 of last 2 quarters. R&D expenses increased from $16.6M in 2025-Q2 to $21.5M in 2026-Q2, while net loss grew from $21.5M to $26.8M over the same period. Management is managing operating losses while increasing investment in R&D, consistent with stated priorities.
“R&D expenses were $21.5 million for 3 months ended June 30, 2026, compared to $16.6 million for same period in 2025.”
“R&D expenses were $21.4 million for 3 months ended March 31, 2026, compared to $14.3 million for same period in 2025.”
Maintain sufficient cash and investments to support clinical milestones and operational investments through late 2027.
Over the trailing year it converted 0.85x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity, the US dollar (low R² over the window).
6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.